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Exploring genetic pleiotropy can provide clues to a mechanism
underlying the observed epidemiological association between type
2 diabetes and heightened fracture risk. We examined genetic vari-
ants associated with bone mineral density (BMD) for association
with type 2 diabetes and glycemic traits in large well-phenotyped
and -genotyped consortia. We undertook follow-up analysis in
;19,000 individuals and assessed gene expression. We queried
single nucleotide polymorphisms (SNPs) associated with BMD at
levels of genome-wide signiﬁcance, variants in linkage disequilib-
rium (r2 . 0.5), and BMD candidate genes. SNP rs6867040, at the
ITGA1 locus, was associated with a 0.0166 mmol/L (0.004) in-
crease in fasting glucose per C allele in the combined analysis.
Genetic variants in the ITGA1 locus were associated with its ex-
pression in the liver but not in adipose tissue. ITGA1 variants
appeared among the top loci associated with type 2 diabetes, fast-
ing insulin, b-cell function by homeostasis model assessment, and
2-h post–oral glucose tolerance test glucose and insulin levels.
ITGA1 has demonstrated genetic pleiotropy in prior studies, and
its suggested role in liver ﬁbrosis, insulin secretion, and bone heal-
ing lends credence to its contribution to both osteoporosis and
type 2 diabetes. These ﬁndings further underscore the link be-
tween skeletal and glucose metabolism and highlight a locus to
direct future investigations. Diabetes 61:2176–2186, 2012
Studies show that adults with type 2 diabetes havea higher fracture rate than those without diabetes(1–5). A meta-analysis of 16 studies revealed a 1.7(95% CI 1.3–2.2) relative risk of hip fracture for
people with diabetes compared with those without diabetes
(6). The higher fracture rate persisted even after considering
factors including, but not limited to, falls, impaired vision,
and weight (4). Quantitative computed tomography studies
show increased bone porosity in individuals with type 2
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diabetes, suggesting that bone integrity is compromised and
thereby causing increased bone fragility (7–9), but it remains
unclear what may be causing the decreased bone integrity.
Despite the generally increased bone mineral density (BMD)
of individuals with type 2 diabetes (1), for the same BMD
measurement, people with type 2 diabetes have a higher risk
of fracture (10). Basic science studies reveal further evi-
dence of a link between bone-derived hormones and glucose
regulation. Mice lacking osteocalcin, an osteoblast-speciﬁc
secreted molecule, have glucose intolerance (11,12).
The relationship between osteoporosis and type 2 dia-
betes raised by these epidemiological studies, and intriguing
new molecular data, hint to a common mechanism impli-
cated in the pathogenesis of both disorders. Discovering
genetic determinants that exhibit genetic pleiotropy (de-
ﬁned as one gene inﬂuencing multiple phenotypic traits)
may point to a common underlying mechanism. Approxi-
mately 16.9% of the genes in the National Human Genome
Research Institute’s catalog of published genome-wide as-
sociation studies (GWASs) are estimated to be pleiotropic
(13). GWASs reveal genetic variants that are associated
with BMD (a quantitative endophenotype for osteoporosis
and a surrogate for fracture risk) (10,14–18). Some of these
loci are also associated with traits seemingly unrelated
to BMD (Table 1). However, common genetic variants
inﬂuencing BMD have not been studied systematically for
association with type 2 diabetes and other glycemic traits.
We therefore performed a comprehensive evaluation of
the inﬂuence of BMD-related genetic loci on diabetes-
related phenotypes. After examining an extensive list of
BMD-related single nucleotide polymorphisms (SNPs) for
association with type 2 diabetes and quantitative glycemic
traits in large GWAS meta-analysis datasets, our top SNPs
were selected for in silico replication in additional cohorts,
cis-gene expression analyses, and BMI association. In this
study, we aimed to underscore the genetic determinants that
are shared between osteoporosis and type 2 diabetes and
provide clues into a commonmechanism that may contribute
to both diseases. Furthermore, through this systematic ex-
ploration, we have generated testable hypotheses for repli-
cation by independent cohorts and experimental follow-up.
RESEARCH DESIGN AND METHODS
SNP selection. In total, 1,778 SNPs were collated for association with type 2
diabetes and glycemic traits (Fig. 1). The SNP selection is described below.
A total of 35 SNPs initially were selected based on BMD GWASs in pop-
ulations of European ancestry (14–17). If multiple SNPs were listed for one
gene per trait, SNPs were kept for analysis if the correlation was low (pairwise
linkage disequilibrium [LD] r2 , 0.5); if r2 $ 0.5, only the SNP with the lowest
P value was kept unless the study indicated that multiple correlated SNPs had a
high degree of explanatory power of the variance for the trait. We removed
TABLE 1
BMD loci associated with non–BMD related traits and disease in GWASs
Locus SNP Trait/disease Reference*
MEF2C rs17421627 Retinal vascular caliber Ikram MK, PLoS Genetics, 2010
rs10037512 Height Lango Allen H, Nature, 2010
rs770189 Tonometry Levy D, BMC Medical Genetics, 2007
SOX6 rs297325 BMI Liu YZ, PLoS One, 2009
MEPE rs7698623 Ischemic stroke among
migraineurs with aura
Schürks M, PLoS One, 2011
MHC rs2516399 Eosinophil count Okada Y, PLoS Genetics, 2011
rs2269426 Eosinophil count Gudbjartsson DF, Nature Genetics, 2009
rs3095254 Monocyte count Okada Y, PLoS Genetics, 2011
rs9271366 Inﬂammatory bowel disease Okada Y, Gastroenterology, 2011
rs7774434 Primary biliary cirrhosis Mells GF, Nature Genetics, 2011
rs34704616 Cognitive test performance Cirulli ET, Eur J Human Genetics, 2010
rs7743761 Ankylosing spondylitis Reveille JD, Nature Genetics, 2010
rs9268866 Ulcerative colitis Barrett JC, Nature Genetics, 2009
rs13194053 Schizophrenia Purcell SM, Nature, 2009
rs6932590 Schizophrenia Stefansson H, Nature, 2009
rs3131296 Schizophrenia Stefansson H, Nature, 2009
rs9272346 Type 1 diabetes WTCCC, Nature, 2007
rs9268645 Type 1 diabetes Barrett JC, Nature Genetics, 2009
rs1265181 Psoriasis Zhang XJ, Nature Genetics, 2009
rs6457617 Rheumatoid arthritis WTCCC, Nature, 2007
ESR1 rs2982694 Sudden cardiac arrest Aouizerat BE, BMC Cardiovasc Disord, 2011
rs4869742 Chronic myeloid leukemia Kim DH, Blood, 2011
rs3734805 Breast cancer Fletcher O, J Natl Cancer Inst, 2011
rs3757318 Breast cancer Turnbull C, Nature Genetics, 2010
rs2046210 Breast cancer Zheng W, Nature Genetics, 2009
rs543650 Height Lango Allen H, Nature, 2010
rs6902771 Alcohol dependence Treutlein J, Arch Gen Psychiatry, 2009
DCDC5 rs3925584 Serum magnesium levels Meyer TE, PLoS Genetics, 2010
TNFRSF11A (RANK) rs3018362 Paget disease Albagha OM, Nature Genetics, 2011
rs2957128 Paget disease Albagha OM, Nature Genetics, 2011
TNFSF11 (RANKL) rs2062305 Crohn disease Franke A, Nature Genetics, 2010
All SNPs listed were associated with the traits/disease at P , 1 3 1025 in GWASs. Table was compiled using www.genome.gov (49). The following
loci were not associated with non–BMD related traits/disease: CTNNB1, ARHGAP1, LRP5, MARK3, HDAC5, SOST, SPTBN1, STARD3NL, SP7,
FOXL1, CRHR1, ZBTB40, GPR177, FLJ42280, and TNFRSF11B (OPG). *The full reference list can be found in the Supplementary Data online.
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rs6696981 (ZBTB40), rs4879055 and rs6929137 (ESR1), rs6993813 and rs6469804
(TNFRSF11), rs9594759 (RANKL), rs1107748 (SOST), rs2566755 (GPR177), and
rs7781370 (FLJ42280) (14,15,17). The ﬁnal list of 26 BMD genome wide–
associated SNPs was examined for association with type 2 diabetes and glycemic
traits (Table 2).
Since the index SNPmay not be the causal variant and other genetic variants
in the region may have a stronger inﬂuence on the traits examined, we tested
the region around the index variant by selecting SNPs in moderate-to-strong LD
(r2 . 0.5). We chose variants in moderate-to-strong LD, rather than all of the
variants in this region, to base our exploration on variants with a higher prior
probability of true association and reduce the multiple testing burden. All SNPs
that were 50 kilobases (kb) upstream and downstream from and in moderate-to-
strong LD with the 26 BMD-related SNPs were tested for association with type 2
diabetes and glycemic traits. These SNPs were identiﬁed using SNP Annotation
and Proxy Search, SNAP (http://www.broadinstitute.org/mpg/snap/) (19) (Sup-
plementary Table 1).
In addition to selecting the 26 SNPs associated at genome-wide signiﬁcance
with BMD and the surrounding region, we selected candidate genes that were
found to be associated (P , 2.39 3 1026 after Bonferroni correction) with
BMD in the GEFOS (Genetic Factors for Osteoporosis) Consortium (20). This
article identiﬁes nine candidate genes, including ESR1, LRP4, ITGA1, LRP5,
SOST, SPP1, TNFRSF11A (RANK), TNRFSF11B, and TNFSF11 (RANKL).
For each gene, we identiﬁed all SNPs within and 20 kb upstream and down-
stream of any transcript of the gene. All SNPs within those boundaries that
were genotyped or imputed in the consortia were tested for association with
type 2 diabetes and glycemic traits (Supplementary Table 1).
Study populations. We tested SNPs in the DIAGRAM+ (Diabetes Genetics
Replication and Meta-analysis) Consortium (21) for association with type 2
diabetes and in MAGIC (Meta-Analyses of Glucose and Insulin-Related Traits
Consortium) (22–24) for association with seven glycemic quantitative traits.
These traits included fasting glucose, fasting insulin, homeostasis model
assessments of b-cell function (HOMA-B) and insulin resistance (HOMA-IR)
(25), hemoglobin A1C (HbA1c), and glucose and insulin levels 2 h post–glucose
load (2-h glucose and 2-h insulin). The DIAGRAM+ Consortium combined
case-control data from eight type 2 diabetes GWASs with up to 42,542 case and
98,912 control subjects of European ancestry (21). MAGIC combined data
from multiple GWASs that identiﬁed loci that affect quantitative glycemic traits.
Its discovery sample included up to 46,186 individuals from 17 population-based
cohorts and 4 case-control studies (22–24). It is noteworthy that the Framingham
Heart Study (FHS), Diabetes Epidemiology: Collaborative Analysis of Diagnostic
Criteria in Europe (deCODE) Study, Erasmus Rucphen Family Study, and
TwinsUK Study provided data to both MAGIC and the BMD datasets from where
the genome-wide–associated SNPs were selected. Using FHS as a representative
cohort of European descent that contained both BMD and glycemic values, we
found phenotypic correlations, r of 0.11–0.16, between bone (femoral neck and
lumbar spine BMD) and glycemic traits (glucose and insulin). Since the pheno-
typic correlation is low, we would not necessarily expect to see a genetic asso-
ciation solely based on the fact that a small portion of the participants were
assessed for both traits. In addition, examining the associations using meta-
analyses of large consortia, rather than in the subset of overlapping participants,
provides a more powerful approach.
The study protocols were approved by the institutional review board of the
respective cohorts’ institutions, and informed consent was obtained from each
subject prior to participation.
Testing for association. After the collation of the index, LD-based, and gene-
based BMD-related SNPs, we tested 1,778 unique SNPs for association with
type 2 diabetes and glycemic traits. We obtained effect estimates and P values
from GWAS meta-analyses provided by DIAGRAM+ and MAGIC. We deter-
mined which SNPs to examine in follow-up studies by calculating a signiﬁcance
threshold for each group of SNPs selected (index, LD-based, and gene-based).
We used a Bonferroni correction for the estimated number of independent tests
after taking LD into account determined using a method proposed by Nyholt
(26) and Li and Ji (27). For our primary analyses, we used a stricter threshold
by accounting for the number of traits tested. We evaluated 26 BMD SNPs
for association with type 2 diabetes and seven glycemic traits (26 tests multi-
plied by 8 traits = 208), yielding thresholds to declare statistical signiﬁcance at
P = 2.4 3 1024 (0.05/208 tests). For the LD- and gene-based secondary analyses,
we corrected for the number of independent SNPs tested but not for the number
of traits examined. The P value threshold for the 513 LD-based SNPs (188 in-
dependent tests) was 2.6 3 1024 and for the 1,318 candidate gene–based SNPs
(651 independent tests), 7.73 1025. A study-wide P value of 6.03 1025 for 1,778
total SNPs (830 independent tests) determined signiﬁcance for the combined
meta-analysis (described below).
Follow-up strategy. To follow up the BMD-related SNPs associated with type
2 diabetes and glycemic traits, we combined in silico GWAS data from 12
additional cohorts of 19,417 nondiabetic participants (Amish Family Diabetes
Study, Atherosclerosis Risk in Communities Study [ARIC], Anglo-Scandinavian
Cardiac Outcomes Trial [ASCOT], Busselton Health Study [BHS], Data From
the Epidemiological Study on the Insulin Resistance Syndrome [DESIR] Study,
French Obese Study, Family Heart Study [FamHS], Fenland Study, Finnish
Twins Study, Swedish Twins Study, GEMINAKAR Study, and the Supplé-
mentation en Vitamines et Minéraux Antioxydants [SU.VI.MAX]) Study (de-
tailed in Supplementary Table 2). We then combined the discovery and
replication meta-analysis results for overall association using METAL (28).
Follow-up SNPs were examined by cis-expression quantitative trait loci
(eQTL) analysis in metabolically relevant tissues, liver, and adipose. Liver tissue
samples came from the Advanced Study of Aortic Pathology (ASAP) cohort of
211 healthy adults undergoing aortic valve surgery. Each biopsy was taken in
RNAlater (Ambion, Austin, TX). RNA quality was analyzed with an Agilent 2100
bioanalyzer (Agilent Technologies, Inc., Palo Alto, CA), and quantity was mea-
sured by NanoDrop (Thermo Scientiﬁc, Waltham, MA). RNA was puriﬁed using
the RNeasy Mini kit (QIAGEN, Hilden, Germany), including treatment with
RNasefree DNase set (QIAGEN) according to the manufacturer’s instructions.
Expression proﬁling was done on the Affymetrix GeneChip Human Exon 1.0 ST
array (Affymetrix, Inc., Santa Clara, CA). Expression data were preprocessed
using the robust multiarray analysis algorithm with quantile normalization, log2
transformation, and the “extended” set of meta probe sets. Genotyping of the
DNA samples was done using Illumina 610wQuad arrays (Illumina, Inc., San
Diego, CA). SNPs were imputed using MACH 1.0 software with a readability
strength quality score $0.6. Each SNP was encoded as 0, 1, or 2 depending on
genotype, and a linear regression model was ﬁtted (29).
Adipose tissue samples came from the Multiple Tissue Human Expression
Resource (MuTHER) (30) of 776 healthy female adult twins. RNA was extracted
from homogenized subcutaneous adipose tissue samples using TRIzol Reagent
(Invitrogen, Grand Island, NY) according to protocol provided by the manufac-
turer. RNA quality was assessed with the Agilent 2100 BioAnalyzer, and the
concentrations were determined using NanoDrop ND-1000 (Thermo Scientiﬁc).
Whole-genome expression proﬁling of the samples was performed using the
Illumina Human HT-12 V3 BeadChips according to the protocol supplied by the
manufacturer. Log2-transformed expression signals were normalized separately
per tissue as follows: quantile normalization was performed across technical
replicates of each individual followed by quantile normalization across all indi-
viduals. Subject DNA was genotyped using a combination of Illumina arrays
(HumanHap300, HumanHap610Q, 1M-Duo, and 1.2MDuo 1M). Untyped HapMap2
(http://hapmap.ncbi.nlm.nih.gov) SNPs were imputed using the IMPUTE soft-
ware package (version 2) (31). Association between all SNPs (minor allele
frequency [MAF] .5%, IMPUTE INFO .0.8) within a gene or within 1 MB of
FIG. 1. Study schema. A staged approach was used to examine BMD-
related SNPs for association with type 2 diabetes and related traits.
BMD-related SNPs were collated from BMD GWASs (14–17), nearby
SNPs (650 kb) in moderate-to-high LD (r2 > 0.5), and SNPs from can-
didate genes (620 kb) identiﬁed in GEFOS (20). A total of 1,778 SNPs
were tested for association with type 2 diabetes in DIAGRAM+ (21) and
seven glycemic traits in MAGIC (22,24). Thirteen SNPs were taken for-
ward for follow-up in a replication cohort (N = 19,417), cis-eQTL analysis
in liver and adipose tissue, and association with BMI.
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the gene transcription start or end site and normalized expression values were
performed using the polygenic linear model incorporating a kinship matrix in
GenABEL followed by the ProbABEL mmscore score test with imputed geno-
types. Age and experimental batch were included as cofactors.
We also tested SNPs that were associated with fasting glucose for associ-
ation with BMI using in silico GWAS data from the GIANT (the Genetic In-
vestigation of Anthropometric Traits) Consortium (32) and for association with
femoral neck and lumbar spine BMD in GEFOS (16).
RESULTS
A total of 26 SNPs associated with BMD at genome-wide
levels of signiﬁcance were tested for association with type 2
diabetes and seven continuous glycemic parameters. None
of the SNPs reached the a priori P value threshold of 2.4 3
1024 using conservative Bonferroni correction. Three SNPs
were nominally associated (P , 0.05) with two diabetes-
related traits: the hip BMD-raising allele (G) of SNP rs87939
(CTNNB1) was nominally associated with lower fasting in-
sulin and lower HOMA-IR, the hip BMD-raising allele (A) of
SNP rs1366594 (MEF2C) was associated with higher fasting
insulin and higher HOMA-IR, and the spine BMD-raising al-
lele (A) of SNP rs1999805 (ESR1) was associated with lower
fasting insulin and lower HOMA-IR (Table 2).
We examined 513 SNPs in moderate-to-strong LD (r2 $
0.5) with the BMD index SNPs for association with type 2
diabetes and glycemic traits. None of the SNPs reached
our prespeciﬁed P value threshold (P = 2.6 3 1024). The G
allele at SNP rs2070852 (ARHGAP1), a near-perfect proxy
for the index SNP rs7932354 (T) (r2 = 0.96), was associated
with higher fasting glucose (b = 0.0104 mmol/L [SE 0.004],
P = 9.0 3 1023) (as would be predicted by the nominal
association of the index SNP with the same trait). The
minor alleles of three SNPs, rs4081640, rs2371445, and
rs2371446, in strong LD (r2 . 0.8) with the index SNP
rs487939 (CTNNB1), were associated with lower fasting
insulin (20.016 [0.005], P , 0.002) and HOMA-IR (20.016
[0.005], P , 0.005) at slightly higher levels of signiﬁcance
compared with the index SNP. Likewise, the major alleles
of three SNPs at ESR1 (rs3020348, rs3020349, and
rs2982554) were associated with lower fasting insulin
(20.01 [0.004], P , 0.01) at a slightly higher level of signiﬁ-
cance than the index SNP rs1999805 (r2 . 0.9). No other
SNPs correlated with the BMD-related index SNPs achieved
signiﬁcance levels ,0.01 (Supplementary Table 1).
We examined 1,318 SNPs from nine BMD candidate genes
for association with type 2 diabetes and glycemic traits
(Supplementary Table 1). Thirteen SNPs at the locus ITGA1
were associated with fasting glucose at signiﬁcance levels
below our prespeciﬁed (Bonferroni-corrected) threshold of
TABLE 2
Twenty-six BMD-associated loci for association with diabetes and quantitative glycemic traits
Chr SNP Gene
BMD-raising
allele/other
Type 2 diabetes Fasting glucose Fasting insulin
Odds ratio
(95% CI) P b (mmol/L) P b (pmol/L) P
SNPs associated at genome-wide levels of signiﬁcance with hip BMD
3 rs87939 CTNNB1 g/a 1.01 (0.97–1.05) 0.80 20.0071 (0.004) 0.05 20.0084 (0.004) 0.03
5 rs1366594 MEF2C a/c 1.01 (0.97–1.05) 0.59 0.0039 (0.004) 0.30 0.0086 (0.004) 0.03
11 rs7117858 SOX6 g/a 1.04 (0.99–1.09) 0.15 0.0052 (0.004) 0.22 20.0064 (0.004) 0.14
11 rs7932354 ARHGAP1 t/c 1.05 (1.0–1.10) 0.03 0.0106 (0.004) 0.01 20.0013 (0.004) 0.76
11 rs3736228* LRP5 c/t 0.99 (0.94–1.06) 0.97 0.0006 (0.006) 0.92 0.0012 (0.006) 0.85
14 rs2010281* MARK3 g/a 1.02 (0.98–1.06) 0.35 20.0027 (0.004) 0.49 20.003 (0.004) 0.46
17 rs228769 HDAC5 g/c 1.01 (0.96–1.06) 0.80 0.0014 (0.005) 0.75 0.0036 (0.005) 0.45
17 rs7220711 SOST g/a 1.01 (0.96–1.05) 0.83 0.006 (0.004) 0.12 0.0022 (0.004) 0.58
17 rs1513670* SOST c/t 1.00 (0.96–1.05) 0.92 0.0058 (0.004) 0.13 0.006 (0.004) 0.14
SNPs associated at genome-wide levels of signiﬁcance with spine BMD
2 rs11898505* SPTBN1 a/g 1.01 (0.97–1.06) 0.63 0.0024 (0.004) 0.56 0.0075 (0.004) 0.08
4 rs1471403 MEPE t/c 0.99 (0.95–1.04) 0.78 20.0005 (0.004) 0.90 20.0072 (0.004) 0.07
6 rs3130340 MHC c/t 1.02 (0.97–1.07) 0.39 0.0079 (0.004) 0.07 20.0083 (0.005) 0.07
6 rs1999805 ESR1 a/g 0.99 (0.95–1.03) 0.57 20.0054 (0.004) 0.14 20.0088 (0.004) 0.02
7 rs1524058 STARD3NL c/t 0.99 (0.95–1.03) 0.61 0.0002 (0.004) 0.95 0.0001 (0.004) 0.98
11 rs16921914 DCDC5 a/g 0.97 (0.93–1.02) 0.20 20.0058 (0.004) 0.16 0.0064 (0.004) 0.14
12 rs10876432 SP7 g/a 1.02 (0.98–1.07) 0.38 0.0009 (0.004) 0.83 20.0009 (0.004) 0.84
16 rs10048146 FOXL1 a/g 1.02 (0.97–1.08) 0.51 20.0074 (0.005) 0.16 20.0038 (0.006) 0.50
17 rs9303521 CRHR1 g/t 1.00 (0.96–1.05) 0.88 20.0031 (0.004) 0.43 0.003 (0.004) 0.46
18 rs3018362* TNFRSF11A
(RANK)
g/a 1.02 (0.97–1.06) 0.42 20.004 (0.004) 0.30 0.0041 (0.004) 0.31
SNPs associated at genome-wide levels of signiﬁcance with hip and spine BMD
1 rs7524102 ZBTB40 g/a 1.02 (0.97–1.08) 0.43 0.0068 (0.005) 0.18 0.0079 (0.005) 0.14
1 rs1430742 GPR177 c/t 1.01 (0.96–1.07) 0.59 20.0005 (0.005) 0.91 0.0026 (0.005) 0.59
6 rs4870044 ESR1 c/t 1.05 (1.00–1.09) 0.05 20.0015 (0.004) 0.70 20.0017 (0.004) 0.69
6 rs1038304 ESR1 a/g 1.02 (0.97–1.05) 0.77 20.0042 (0.004) 0.25 20.0013 (0.004) 0.72
7 rs4729260 FLJ42280 c/g 0.99 (0.96–1.04) 0.93 0.003 (0.004) 0.46 0.0059 (0.004) 0.16
8 rs4355801 TNFRSF11B
(OPG)
g/a 1.04 (0.99–1.08) 0.08 0.0068 (0.004) 0.07 0.003 (0.004) 0.43
13 rs9594738 TNFSF11
(RANKL)
c/t 1.01 (0.97–1.05) 0.77 20.0024 (0.004) 0.52 0.0039 (0.004) 0.31
Continued on p. 2180
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7.73 1025, of which 8 were below the study-wide signiﬁcance
threshold (Table 3 and Fig. 2). By assembling an in silico
replication sample of 19,417 individuals, we achieved .75%
power (a = 0.05) to detect 1 SD difference in fasting glucose.
Therefore, the top 13 ITGA1 SNPs were examined for asso-
ciation with fasting glucose in the 12 additional cohorts. The
major C allele of SNP rs6867040 was nominally associated
with higher fasting glucose (P = 0.03) in a directionally con-
sistent manner. None of the 13 SNPs reached genome-wide
signiﬁcance (P , 5 3 1028) in the combined meta-analysis
(Table 3). It is notable that variants in this locus, ITGA1, were
noted to be among the top 10 most signiﬁcant associations for
ﬁve additional traits: type 2 diabetes, fasting insulin, HOMA-B,
and 2-h glucose and insulin levels (Table 4).
To investigate the mechanism by which ITGA1 might
inﬂuence type 2 diabetes and related traits, we examined
the effect of these 13 SNPs on cis-gene expression of ITGA1
in liver and adipose tissue using eQTL analysis. ITGA1 ex-
pression was measured in adipose tissue using a 50–base
pair probe (chromosome 5:52,284,986–52,285,035) available
on the Illumina array and in liver tissue with a set of probes
covering the length of the ITGA1 region (including the gene
PELO) on the Affymetrix array. The major allele of six SNPs
was associated with increased expression (b ranged from
0.089 to 0.107 [SE 0.043–0.044]) of ITGA1/PELO in liver
tissue at P , 0.05, but no SNPs were associated with
ITGA1 expression in adipose tissue (Table 5). Of note, in
adipose tissue, the major alleles of the 13 SNPs were
highly associated with lower PELO expression (effect
estimates ;0.05 [SE ;0.01], lowest P , 2.0 3 1024). To
determine whether PELO or ITGA1 gene expression was
driving the association seen in liver tissue of the ITGA1
expression, we examined probes for each exon in-
dividually. We noted that for all of the genetic variants, the
SNPs appeared to have a stronger association with the
ITGA1-speciﬁc probes than PELO-speciﬁc probes (an ex-
ample ﬁgure of one of the SNPs, rs10512997, is provided in
the Supplementary Data). ITGA1 and PELO are both
expressed in liver, adipose, and pancreatic islets, although
ITGA1 appears to have higher expression in these tissues
(Supplementary Data).
We examined 13 SNPs in ITGA1 for association with
BMI in the GIANT Consortium and BMD in the GEFOS
Consortium. The major allele of seven SNPs was asso-
ciated with higher BMI at P , 0.05 (Table 5). None of
these SNPs were associated with femoral neck and
lumbar spine BMD, although they trended toward low-
ering BMD.
TABLE 2
Continued
HOMA-B HOMA-IR HbA1c 2-h glucose 2-h insulin
Refb P b P b (%) P
b
(mmol/L) P
b
(mmol/L) P
20.0026 (0.003) 0.42 20.0103 (0.004) 0.01 20.0042 (0.006) 0.49 0.003 (0.019) 0.87 20.0073 (0.012) 0.54 (16)
0.0032 (0.003) 0.34 0.01 (0.004) 0.02 20.0001 (0.006) 0.99 0.0167 (0.02) 0.40 20.004 (0.012) 0.75 (16)
20.0076 (0.004) 0.04 20.0052 (0.005) 0.26 20.0071 (0.007) 0.33 0.0075 (0.022) 0.73 20.0205 (0.014) 0.14 (16)
20.0044 (0.004) 0.22 0.0013 (0.004) 0.76 20.0002 (0.007) 0.98 20.0028 (0.02) 0.89 0.0089 (0.013) 0.49 (16)
0.0 (0.006) 0.99 0.0024 (0.007) 0.71 0.0018 (0.009) 0.85 20.0172 (0.03) 0.57 0.0136 (0.019) 0.47 (17)
0.0003 (0.004) 0.94 20.0015 (0.004) 0.73 20.0014 (0.007) 0.84 20.0085 (0.02) 0.67 20.0036 (0.012) 0.77 (15)
0.0029 (0.004) 0.47 0.0028 (0.005) 0.56 0.0063 (0.008) 0.41 0.0071 (0.023) 0.76 20.0066 (0.015) 0.65 (16)
20.0004 (0.003) 0.92 0.0032 (0.004) 0.44 0.0052 (0.006) 0.42 20.0079 (0.019) 0.68 20.0153 (0.012) 0.21 (15)
0.0045 (0.004) 0.21 0.0078 (0.004) 0.07 0.0019 (0.006) 0.76 0.0017 (0.02) 0.93 20.0002 (0.013) 0.99 (15)
20.0006 (0.004) 0.87 0.0073 (0.004) 0.10 0.0167 (0.007) 0.01 20.0522 (0.021) 0.01 20.0243 (0.013) 0.05 (16)
20.0029 (0.004) 0.40 20.0061 (0.004) 0.15 0.0035 (0.006) 0.58 0.0014 (0.02) 0.94 0.0 (0.012) 1.00 (16)
20.0032 (0.004) 0.40 20.0057 (0.005) 0.23 0.0096 (0.008) 0.23 0.0245 (0.023) 0.28 20.0125 (0.014) 0.37 (14)
20.0051 (0.003) 0.13 20.0086 (0.004) 0.03 0.0115 (0.006) 0.06 0.024 (0.02) 0.23 0.001 (0.012) 0.93 (14)
0.0013 (0.003) 0.71 0.0013 (0.004) 0.75 20.0052 (0.006) 0.39 20.0106 (0.02) 0.59 0.0073 (0.013) 0.57 (16)
0.0068 (0.004) 0.06 0.0046 (0.005) 0.30 0.0058 (0.007) 0.42 20.0167 (0.021) 0.42 20.0046 (0.014) 0.74 (16)
20.0022 (0.004) 0.56 20.002 (0.005) 0.67 0.0019 (0.007) 0.78 20.0166 (0.021) 0.43 20.0064 (0.013) 0.62 (15)
20.0013 (0.005) 0.78 20.0036 (0.006) 0.53 0.0116 (0.01) 0.24 20.0467 (0.026) 0.08 20.0159 (0.018) 0.38 (16)
0.0015 (0.004) 0.66 0.0026 (0.004) 0.54 20.0052 (0.006) 0.41 0.0491 (0.02) 0.01 0.0221 (0.013) 0.09 (16)
0.0068 (0.003) 0.05 0.0034 (0.004) 0.42 0.0082 (0.007) 0.22 0.0117 (0.02) 0.55 20.0039 (0.012) 0.75 (15)
0.0013 (0.005) 0.78 0.0067 (0.006) 0.23 0.0022 (0.008) 0.79 20.0235 (0.026) 0.37 20.0134 (0.016) 0.40 (14)
0.0015 (0.004) 0.72 0.0033 (0.005) 0.51 20.0119 (0.008) 0.12 20.03 (0.024) 0.22 20.0225 (0.015) 0.14 (16)
20.0024 (0.004) 0.50 20.0025 (0.004) 0.56 0.0024 (0.007) 0.73 20.022 (0.021) 0.30 0.0112 (0.013) 0.39 (14)
0.0015 (0.003) 0.65 20.002 (0.004) 0.61 0.006 (0.006) 0.31 0.0096 (0.020) 0.62 0.0128 (0.012) 0.28 (14)
0.0043 (0.004) 0.25 0.0054 (0.004) 0.23 0.0004 (0.007) 0.95 0.0243 (0.021) 0.25 0.0002 (0.013) 0.99 (16)
20.0029 (0.003) 0.38 0.0033 (0.004) 0.41 20.0032 (0.006) 0.60 0.0267 (0.019) 0.16 20.0132 (0.012) 0.27 (17)
0.0058 (0.003) 0.09 0.006 (0.004) 0.14 0.0113 (0.006) 0.06 20.016 (0.019) 0.40 0.0101 (0.012) 0.41 (14)
SEs are shown below the effect estimate; conversion factor (mmol/L 3 18 = mg/L). Ref, article where the genome-wide association for the
respective SNP was described. *SNP also is associated with low trauma fracture. Chr, chromosome.
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DISCUSSION
By exploring genetic pleiotropy, we revealed a locus that
may provide clues to a mechanism underlying the observed
epidemiological association between type 2 diabetes and
heightened fracture risk. We compiled a comprehensive list
of BMD-related SNPs composed of genetic variants associ-
ated with BMD at levels of genome-wide signiﬁcance, var-
iants in moderate-to-strong LD with the index SNPs, and
SNPs in BMD candidate genes. By examining these BMD-
related SNPs for association with type 2 diabetes and
glycemic traits, we discovered that SNPs in the ITGA1 locus,
a BMD candidate gene, are suggestively associated with
fasting glucose at study-wide levels of signiﬁcance. The
major alleles of these 13 highly correlated SNPs (CEU
HapMap [Utah residents with ancestry from northern and
western Europe] r2 . 0.7) consistently raised fasting
TABLE 3
SNPs in ITGA1 associated with fasting glucose Stage 1 and taken forward for replication
SNP Function
Effect/other
allele
Stage 1
(up to 46,262 participants)
Replication (Stage 2)
(up to 19,417
participants)
Combined
(up to 64,188
participants)
b (SE) P value b (SE) P value b (SE) P value
rs6881900 Intronic enhancer a/g 0.0167 (0.004) 3.131025 0.0092 (0.006) 0.14 0.0151 (0.003) 9.131026
rs17209725 Intronic c/t 0.0164 (0.004) 3.931025 0.0109 (0.006) 0.08 0.0154 (0.003) 6.231026
rs17209760 Intronic enhancer c/g 0.0164 (0.004) 3.931025 0.0108 (0.006) 0.08 0.0154 (0.003) 6.331026
rs10512997 Intronic c/t 0.0164 (0.004) 3.931025 0.0088 (0.006) 0.15 0.0148 (0.003) 1.431025
rs7716758 Upstream a/t 0.0165 (0.004) 4.131025 0.0113 (0.006) 0.07 0.0156 (0.003) 5.131026
rs12188019 Intronic enhancer t/c 0.0163 (0.004) 4.331025 0.0109 (0.006) 0.08 0.0154 (0.003) 6.731026
rs10940273 Intronic c/a 0.0176 (0.004) 4.531025 0.0103 (0.007) 0.15 0.0165 (0.004) 9.631026
rs6878212 Intronic t/a 0.0163 (0.004) 4.731025 0.0109 (0.006) 0.08 0.0153 (0.003) 6.831026
rs6867040 Intronic enhancer c/t 0.0165 (0.004) 6.731025 0.0142 (0.007) 0.03 0.0166 (0.004) 2.331026
rs6450088 Intronic a/g 0.0158 (0.004) 6.731025 0.0104 (0.006) 0.10 0.0148 (0.003) 1.431025
rs12153381 Intronic enhancer c/t 0.0157 (0.004) 6.931025 0.0092 (0.006) 0.14 0.0144 (0.003) 1.631025
rs10512998 Intronic enhancer a/t 0.0156 (0.004) 7.231025 0.0092 (0.006) 0.14 0.0143 (0.003) 1.731025
rs11886 Intronic t/g 0.0156 (0.004) 7.431025 0.0094 (0.006) 0.13 0.0144 (0.003) 1.731025
rs13179969* Intronic g/a 20.0013 (0.004) 0.76
Eight SNPs in ITGA1 were associated with fasting glucose below our study-wide P value threshold (P = 6.0 3 1025, in boldface type) in the 21
discovery cohorts of MAGIC. The top 13 SNPs were promoted for follow-up with fasting glucose in 12 additional cohorts with in silico
genotype data. A combined analysis was then performed. SNP function was determined using FastSNP search (50). bs are expressed in mmol/L
(conversion: mmol/L 3 18 = mg/L). Boldfaced alleles are the major allele per HapMap CEU. *rs13179969 major allele (G) was associated with
lower lumbar spine BMD (b = 20.07 g/cm2) in a candidate gene study at study-wide signiﬁcance (P = 9.6 3 1027) (20).
FIG. 2. SNPs at BMD-associated ITGA1 associated with fasting glucose. Thirteen SNPs (red diamonds) in ITGA1 were associated with fasting
glucose levels (P < 7.7 3 1025) in the MAGIC discovery cohorts, with 1 SNP (rs6867040) replicating at nominal signiﬁcance (P < 0.05) in 12
replication cohorts. SNP rs13179969 (blue diamond) (ITGA1) was associated with lumbar spine BMD in GEFOS at 9.6 3 1027 (20). This SNP is not
associated with fasting glucose in MAGIC. LD is indicated by size of the diamond.
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glucose in the discovery and replication stages. In addi-
tion, genetic variants of ITGA1 appear among the top 10
genetic variants for association with ﬁve additional traits:
type 2 diabetes, fasting insulin levels, HOMA-B, 2-h glucose
levels, and 2-h insulin levels. The major alleles at these
SNPs appear to be associated with higher ITGA1 expres-
sion in the liver and higher BMI. We highlight that genetic
variation in ITGA1 may not only explain increased bone
fragility but also contribute to fasting glucose levels.
ITGA1 encodes the a-1 subunit integrin, which hetero-
dimerizes to form the a1b1-integrin cell surface recep-
tor for laminin and collagen. Integrins are transmembrane
glycoproteins involved in cell adhesion to the extracellular
matrix. They are also signaling molecules for regulation of
apoptosis, gene expression, cell proliferation, invasion and
metastasis, and angiogenesis (33). Less is known about the
PELO gene in humans, which overlaps the ITGA1 sequence
at the 59 end (Fig. 2) and has been more extensively studied
in Drosophila. Human and Drosophila homologs share 70%
sequence identity. PELO is thought to be involved in mitosis
and meiosis (e.g., spermatogenesis) in many tissues (34), but
its involvement in bone and glucose disease is unknown.
The ITGA1 locus was initially chosen for our study be-
cause it was found to contain an intronic SNP, rs13179969,
TABLE 4
Top 10 BMD-related SNPs, direction of effect, and level of signiﬁcance for association with type 2 diabetes and glycemic traits
Type 2 diabetes HbA1c Fasting insulin
E/O P E/O P E/O P
ITGA1 (Chr 5) DUSP3 (Chr 17) ESR1 (Chr 6)
rs17208683 a/g ↑ 0.002 rs1230397 t/c ↓ 0.004 rs3020410 a/c ↑ 0.001
rs11745801 a/g ↑ 0.003 rs4793026 a/g ↓ 0.005 rs9341052 a/g ↑ 0.004
rs17274300 g/t ↑ 0.007 rs17742347 t/c ↑ 0.006 rs9371564 a/g ↑ 0.006
TNFRSF11B (Chr 8) rs3785810 c/g ↓ 0.006 CTNNB1 (Chr 3)
rs9642843 a/c ↑ 0.007 rs11713 a/g ↑ 0.006 rs4081640 t/g ↓ 0.001
rs7829123 a/c ↑ 0.007 rs1234612 t/c ↓ 0.006 rs2371445 a/g ↓ 0.002
rs7835846 c/t ↑ 0.007 TNFRSF11B (Chr 8) rs2371446 t/g ↓ 0.002
rs12677975 c/t ↑ 0.009 rs12675217 a/g ↓ 0.006 SOST (Chr 17)
rs11573849 g/t ↑ 0.010 rs9642843 a/c ↓ 0.007 rs17610252 a/t ↓ 0.004
rs11573828 c/t ↑ 0.010 rs7829123 a/c ↓ 0.008 ITGA1 (Chr 5)
LRP4 (Chr 11) LRP5 (Chr 11) rs2452868 a/t ↑ 0.005
rs13448 c/t ↑ 0.007 rs7924398 t/c ↑ 0.007 rs2938789 t/c ↓ 0.007
HOMA-B HOMA-IR
E/O P E/O P
ITGA1 (Chr 5) CTNNB1 (Chr 3)
rs1466445 t/c ↑ 0.0006 rs4081640 t/g ↓ 0.003
rs2452864 a/g ↓ 0.0008 rs2371445 a/g ↓ 0.003
rs2934215 t/g ↓ 0.001 rs2371446 t/g ↓ 0.005
rs2934216 a/g ↑ 0.001 rs430727 t/c ↓ 0.005
rs2456216 a/g ↑ 0.001 ESR1 (Chr 6)
rs2047067 a/g ↑ 0.001 rs9479129 t/c ↓ 0.004
rs2452869 t/c ↑ 0.001 rs9371564 a/g ↑ 0.006
rs2447869 t/c ↑ 0.001 rs3020410 a/c ↑ 0.007
rs9686276 a/c ↑ 0.001 MEF2C (Chr 5)
rs10038838 a/c ↑ 0.001 rs430727 t/c ↑ 0.005
rs10037512 t/g ↑ 0.007
2-h glucose 2-h insulin
E/O P E/O P
ESR1 (Chr 6) ITGA1 (Chr 5)
rs827420 a/g ↓ 0.005 rs17274300 t/g ↑ 0.0008
rs712221 a/t ↑ 0.06 rs17208683 a/g ↑ 0.001
rs1514348 t/g ↑ 0.06 rs11745801 a/g ↑ 0.001
rs827419 a/c ↑ 0.06 ESR1 (Chr 6)
rs1709184 t/c ↑ 0.05 rs3798758 a/c ↓ 0.002
rs1709182 t/c ↑ 0.06 rs926848 t/c ↓ 0.003
TNFRSF11B (Chr 8) rs1801132 c/g ↑ 0.003
rs4876868 a/g ↓ 0.005 rs9341086 a/c ↓ 0.003
rs11573856 t/c ↑ 0.01 rs827419 a/c ↑ 0.004
rs11573869 a/g ↓ 0.01 rs1709182 t/c ↑ 0.005
ITGA1 (Chr 5) rs1709184 t/c ↑ 0.006
rs7730842 t/c ↑ 0.01
Underlined SNPs are in moderate-to-strong LD with SNPs associated with BMD in GWASs. Top fasting glucose SNPs are listed in Table 3. E/O,
effect/other allele. Chr, chromosome. Arrows indicate the direction of effect. Gene name is indicated followed by the chromosomal location in
parentheses.
BONE-RELATED GENES AND GLYCEMIC TRAITS
2182 DIABETES, VOL. 61, AUGUST 2012 diabetes.diabetesjournals.org
whose G major allele had been associated with lower
lumbar spine BMD at levels of study-wide signiﬁcance (P =
9.6 3 1027) (20). This SNP was not associated with fasting
glucose in our study, nor is it in strong LD with the 13
SNPs followed up in this study (r2 , 0.05, HapMap CEU)
(Fig. 2). Despite low LD between these SNPs, they point to
a locus, ITGA1, in which in vivo and in vitro models have
a suggested role in both bone disease and glucose homeo-
stasis. Null ITGA1 mice have impaired fracture healing and
cartilage remodeling (35), although it is not yet clear what
role this gene product has on BMD or bone structure in
animal models. Furthermore, integrins have been examined
in an effort to culture and expand human b-cells for human
transplantation ex vivo (36). The a1b1-integrins appear to
play a role in b-cell insulin secretion, migration, and mes-
enchymal transformation (37).
The mechanism by which ITGA1 may inﬂuence fasting
glucose is not entirely clear. Fasting glucose is an estimate
of hepatic glucose production after an overnight fast and
can indicate hepatic and peripheral insulin resistance (38).
Our follow-up gene expression studies suggest that ITGA1
genetic variation may affect fasting glucose via the liver
rather than adipose tissue. We found that the major alleles
of six of the SNPs tested were correlated with increased
hepatic expression of ITGA1 (P , 0.05). In addition, the
same top three SNPs were associated with both type 2
diabetes and 2-h insulin level, suggesting that the mecha-
nism may involve insulin resistance. Some studies suggest
a role of integrins in insulin resistance (39). Integrins are
thought to play a key role in the evolution of liver ﬁbrosis
brought on by inﬂammation as seen in insulin resistance–
associated nonalcoholic steatohepatitis (39).
In mice, the inﬂuence of ITGA1 and ITGA2 (encoding
the a-2 component of a2b1-integrin) on the effect of in-
flammation on insulin resistance in muscle induced by a high-
fat diet has been examined recently (40). The high-fat diet
induced extracellular matrix changes by increasing collagen
accumulation in muscle. The itga22/2 mice on a high-fat
diet had lower basal glucose than itga2+/+ mice, suggesting
that the extracellular matrix–integrin signaling plays a role
in insulin resistance in muscle. The same observation was
not seen for itga12/2 and itga1+/+ mice. Given our study’s
gene expression ﬁndings and the role of integrins in the liver
in response to inﬂammation and insulin resistance, further
investigation of the liver in itga1 null mice in response to
inﬂammation could reveal more information about the role
of ITGA1 in hepatic glucose production. Ultimately, our
study remains hypothesis generating and highlights a novel
locus that links BMD and fasting glucose that warrants fur-
ther investigation.
This study suggests that ITGA1 may exhibit genetic
pleiotropy through its association with BMD and fasting
glucose. True pleiotropy is difﬁcult to conﬁrm, especially if
a causal relationship exists between fasting glucose and
BMD, as such a ﬁnding suggests the possibility of a medi-
ating effect of one phenotype on the other. The evidence of
such a causal relationship between fasting glucose and
bone density is not completely consistent. Although in
vitro studies show that chronic hyperglycemia may impair
osteoblast function (41,42), clinical studies demonstrate
that individuals with type 2 diabetes have lower bone turn-
over (43), which usually indicates a more optimal skeletal
state. On the other hand, those with poorly controlled di-
abetes have been shown to have improvement in BMD
measured by bone densitometry after 1 year of tightened
control (44). Therefore, it is not possible to clearly establish
a direct link between hyperglycemia and BMD (45). Like-
wise, if there was a common intermediate phenotype driving
the relationship between BMD and fasting glucose, then our
ﬁndings may not indicate true genetic pleiotropy. BMI could
be considered a potential intermediate phenotype because it
is correlated with both type 2 diabetes pathogenesis and
BMD (46,47). We examined the ITGA1-related SNPs for
association with BMI in the GIANT Consortium (32). Several
of the variants reached a nominal level of signiﬁcance
(lowest P = 0.007) for association with BMI (Table 4). These
data suggest that ITGA1 may act on BMD or fasting glucose
through the intermediate phenotype of BMI. Although the
ITGA1 locus has not been associated with BMI in the past,
the intronic SNP rs7723398 (r2, 0.3 per CEU with the SNPs
followed up in this study) has been found to be associated
with another anthropometric trait, brachial circumference
(P = 9.7 3 1026), in a Croatian population (48).
The strengths of our study include the comprehensive
bone-related SNP selection from recently published GWAS
data and the ability to test them in very large, well-phenotyped
TABLE 5
Association of ITGA1 genetic variation with ITGA1 RNA expression and BMI
SNP
Effect/other
allele
Association of SNPs with ITGA1 eQTL Association of SNPs with BMI
Liver Adipose BMI
b (SE) P b (SE) P b (SE) P
rs6867040* c/t 0.073 (0.043) 0.09 20.018 (0.013) 0.21 0.012 (0.005) 0.03
rs7716758 a/t 0.064 (0.043) 0.15 20.015 (0.014) 0.16 0.011 (0.005) 0.04
rs12188019* t/c 0.071 (0.043) 0.10 20.018 (0.013) 0.17 0.011 (0.005) 0.04
rs17209725* c/t 0.084 (0.043) 0.05 20.018 (0.013) 0.18 0.011 (0.005) 0.04
rs6878212* t/a 0.07 (0.043) 0.11 20.018 (0.013) 0.17 0.011 (0.005) 0.04
rs17209760* c/g 0.084 (0.043) 0.05 20.018 (0.013) 0.18 0.011 (0.005) 0.04
rs6450088 a/g 0.094 (0.043) 0.03 20.018 (0.014) 0.34 0.009 (0.005) 0.07
rs11886* t/g 0.089 (0.043) 0.04 20.015 (0.013) 0.25 0.01 (0.005) 0.06
rs10940273 c/a 0.078 (0.044) 0.08 20.018 (0.014) 0.20 0.015 (0.006) 0.007
rs10512998 a/t 0.107 (0.043) 0.01 20.015 (0.013) 0.28 0.01 (0.005) 0.05
rs12153381 c/t 0.1 (0.043) 0.02 20.015 (0.013) 0.26 0.01 (0.005) 0.05
rs6881900 a/g 0.099 (0.043) 0.02 20.015 (0.013) 0.28 0.01 (0.005) 0.05
rs10512997 c/t 0.095 (0.043) 0.03 20.015 (0.013) 0.28 0.01 (0.005) 0.05
*SNP overlies both ITGA1 and PELO gene. The boldfaced P values denote nominal signiﬁcance (P , 0.05).
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type 2 diabetes and glycemic traits consortia. We were
able to replicate our ﬁndings from the discovery phase in
an additional ;19,000 individuals. We also followed up the
genetic variants with eQTL analysis and other related
traits. Our results may help explain the, as yet not quite
well understood, epidemiological link between type 2 dia-
betes and bone disease. This study has highlighted the ne-
cessity to examine genetic variants not reaching the
genome-wide signiﬁcance threshold because this may
uncover potential ﬁndings buried in the P value distribution.
Given that the MAGIC discovery dataset has been published
since the completion of our analyses, further studies like
ours can be pursued (www.magicinvestigators.org). Fur-
thermore, the BMD-related locus that was associated with
fasting glucose was selected from a candidate gene study.
This illustrates the importance of examining candidate genes
in discovering genetic pleiotropy rather than solely exam-
ining loci associated at levels of genome-wide signiﬁcance.
We are limited by having chosen SNPs from GWASs ex-
amining only BMD. Even though BMD is predictive of
fracture in people with type 2 diabetes (10), studies show
that individuals with type 2 diabetes have a higher risk of
fracture despite higher BMD in general (4). By examining
genetic variants related to BMD only, we may miss the non–
BMD related genetic contribution to fracture risk. In addi-
tion, our ﬁndings do not explain the observed paradox of
generally higher BMD and yet higher fracture risk among
people with type 2 diabetes (4). A direct genetic test of this
paradox using ITGA1 SNPs is not possible because the
SNPs that inﬂuence fasting glucose and BMD at this locus
are not correlated. In addition, a follow-up study examining
fracture-related genetic variants for association with type 2
diabetes and glycemic traits will be warranted when large
fracture GWASs become available. In a similar manner, the
examination of glycemia-related SNPs for association with
BMD and fracture phenotypes may further explain the re-
lationship between bone disease and type 2 diabetes, and
these studies are currently under way.
Despite the large sample size, none of the SNPs reached
genome-wide signiﬁcance in the combined analysis. We
may need a larger sample size to determine if the ITGA1
SNPs that were associated with fasting glucose will repli-
cate in other populations and attain genome-wide signiﬁ-
cance because our replication sample may have been too
small to detect the association found in the discovery stage.
We estimate that we need an additional 12,000 participants
to see an association between the ITGA1 SNPs and fasting
glucose at the same effect sizes seen in the discovery stage.
Fortunately, ongoing deployment of the custom-made
Metabo-Chip (comprising .200,000 SNPs related to cardio-
vascular disease, obesity, and type 2 diabetes) across many
thousands of samples with relevant phenotypes may provide
sufﬁcient power to uncover novel associations at genome-
wide signiﬁcance levels. The ITGA1 SNPs rs6881900 and
rs10940273, found to be associated with fasting glucose in
our study, are present in the Metabo-Chip. This provides an
exciting opportunity to understand the relationship of ITGA1
with glycemic traits, as well as other metabolic phenotypes in
cardiovascular disease and obesity.
In sum, we have identiﬁed a new locus candidate, ITGA1,
inﬂuencing both fasting glucose and BMD, that may begin to
explain the genetic contribution to the epidemiological obser-
vations linking type 2 diabetes and osteoporosis. The ongoing
analysis of Metabo-Chip genotypes across large samples will
help determine if ITGA1 proves to be a new locus associated
with fasting glucose at levels of genome-wide signiﬁcance.
New insights into the genetic pleiotropy of both disease states
may further underscore the link between skeletal and glucose
metabolism, highlight the complexity of this relationship, pro-
vide a focus for future investigations, raise awareness for
adverse effects in one system while treating another, and re-
veal potential targets for disease therapies in both diseases.
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